News headlines about The Advisory Board Company (NASDAQ:ABCO) have trended positive this week, according to Alpha One. The research group, a unit of Accern, rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. The Advisory Board Company earned a media sentiment score of 0.37 on Alpha One’s scale. Alpha One also gave news coverage about the business services provider an impact score of 78 out of 100, meaning that recent press coverage is likely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected AlphaOne’s analysis:
- What is the fair value of The Advisory Board Company (ABCO) (simplywall.st)
- Dr. Andrea Califano Joins Tempus Scientific Advisory Board and Tempus and DarwinHealth Partner on Research Initiative (feeds.benzinga.com)
- Shares of ABCO Up 24.4% Since Uptrend Call on Shares (mysmartrend.com)
- Rheumatology Leaders Oppose Sweeping Healthcare Cuts in Trump Administration Budget (feeds.benzinga.com)
- The Advisory Board Company (ABCO) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
Shares of The Advisory Board Company (NASDAQ:ABCO) traded down 0.49% during trading on Friday, hitting $51.15. The stock had a trading volume of 20,930 shares. The firm’s 50-day moving average is $49.50 and its 200-day moving average is $42.73. The Advisory Board Company has a one year low of $24.85 and a one year high of $54.50. The firm has a market cap of $2.08 billion, a P/E ratio of 20.73 and a beta of 1.15.
The Advisory Board Company (NASDAQ:ABCO) last released its earnings results on Thursday, May 4th. The business services provider reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.12. The firm had revenue of $194.50 million during the quarter, compared to analyst estimates of $188.43 million. The Advisory Board Company had a negative net margin of 5.77% and a positive return on equity of 11.28%. The business’s revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.44 EPS. Equities research analysts forecast that The Advisory Board Company will post $1.97 EPS for the current year.
ABCO has been the subject of a number of research analyst reports. Zacks Investment Research cut The Advisory Board Company from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. Robert W. Baird raised The Advisory Board Company from a “neutral” rating to an “outperform” rating and upped their target price for the company from $50.00 to $53.00 in a research report on Monday, March 27th. SunTrust Banks, Inc. cut The Advisory Board Company from a “buy” rating to a “hold” rating and set a $45.00 target price for the company. in a research report on Friday, March 10th. Barclays PLC set a $56.00 target price on The Advisory Board Company and gave the company a “buy” rating in a research report on Tuesday, February 14th. Finally, Craig Hallum cut The Advisory Board Company from a “buy” rating to a “hold” rating and set a $46.00 target price for the company. in a research report on Wednesday, March 1st. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $47.92.
In other The Advisory Board Company news, insider Evan R. Farber sold 5,656 shares of the business’s stock in a transaction on Friday, March 24th. The shares were sold at an average price of $48.00, for a total transaction of $271,488.00. Following the completion of the transaction, the insider now owns 5,656 shares of the company’s stock, valued at approximately $271,488. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President David L. Felsenthal sold 32,000 shares of the business’s stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $45.01, for a total transaction of $1,440,320.00. Following the transaction, the president now directly owns 85,256 shares of the company’s stock, valued at approximately $3,837,372.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 83,856 shares of company stock valued at $3,867,680. Company insiders own 2.90% of the company’s stock.
About The Advisory Board Company
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company offers subscription-based membership programs, software and data-enabled services. All of its programs are rooted in best practices and extends across four areas, including Best practices research, Technology, Data-enabled services and Consulting services.
Receive News & Ratings for The Advisory Board Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Company and related companies with our FREE daily email newsletter.